ARVN ARVINAS, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1655759 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-11.8%
TTM net income YoY83.8%
TTM EPS YoY90.1%
Revenue 3-yr CAGR18.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-12.1%
Net margin-3.5%
FCF margin-58.0%
EBITDA margin-11.2%
Returns
ROE-1.8%
ROA-1.3%
ROIC (approx.)-5.9%
Asset turnover0.38x
Leverage & solvency
Liabilities / assets15.4%
Debt / equity0.00x
Current ratio8.39x
Interest coverage—
Cash quality & payout
Operating cash flow / net income16.66x
Accruals ratio20.5%
Payout ratio—
Capex / revenue0.5%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $262.60M | $263.40M | $78.50M | $131.40M | $53.60M |
| R&D expense | $285.20M | $348.20M | $379.70M | $315.00M | $180.40M |
| SG&A expense | $95.90M | $165.40M | $100.30M | $79.60M | $61.60M |
| Operating income | -$118.50M | -$250.20M | -$401.50M | -$263.20M | -$188.40M |
| Interest expense | — | $0 | $0 | $0 | $0 |
| Pretax income | -$80.50M | -$198.30M | -$363.90M | -$251.00M | -$184.10M |
| Income tax | $300,000 | $600,000 | $900,000 | $20.90M | $0 |
| Net income | -$80.80M | -$198.90M | -$367.30M | -$282.50M | -$191.00M |
| EBITDA | -$115.50M | -$245.60M | -$396.70M | -$256.90M | -$183.60M |
| EPS (basic) | -1.14 | -2.77 | -6.62 | -5.31 | -3.82 |
| EPS (diluted) | -1.14 | -2.77 | -6.62 | -5.31 | -3.82 |
| Weighted avg. shares (diluted) | 70.90M | 71.90M | 55.50M | 53.20M | 50.00M |
| Balance sheet | |||||
| Cash & equivalents | $142.90M | $100.50M | $311.70M | $86.80M | $112.80M |
| Short-term investments | $542.50M | $938.90M | $949.30M | $1.12B | $1.39B |
| Receivables | $1.00M | $5.70M | $0 | $1.00M | $15.00M |
| Current assets | $700.70M | $1.07B | $1.28B | $1.24B | $1.55B |
| PP&E, net | $5.20M | $7.00M | $11.50M | $13.40M | $12.70M |
| Total assets | $717.90M | $1.09B | $1.30B | $1.27B | $1.58B |
| Current liabilities | $142.50M | $229.80M | $257.10M | $295.10M | $261.70M |
| Short-term debt | $200,000 | $200,000 | $200,000 | $0 | — |
| Long-term debt | $400,000 | $600,000 | $800,000 | $1.00M | $1.00M |
| Total debt | $600,000 | $800,000 | $1.00M | $1.00M | $1.00M |
| Total liabilities | $284.00M | $529.70M | $644.60M | $703.90M | $799.90M |
| Shareholders' equity | $433.90M | $561.70M | $660.00M | $564.90M | $781.70M |
| Net debt | -$142.30M | -$99.70M | -$310.70M | -$85.80M | -$111.80M |
| Shares outstanding | 63.50M | 68.80M | 68.00M | 53.20M | 53.00M |
| Cash flow statement | |||||
| Operating cash flow | -$273.80M | -$259.30M | -$347.80M | -$273.50M | $559.40M |
| Capital expenditure | $1.90M | $1.80M | $2.90M | $6.80M | $4.70M |
| Free cash flow | -$275.70M | -$261.10M | -$350.70M | -$280.30M | $554.70M |
| Investing cash flow | $407.60M | $34.70M | $203.50M | $242.80M | -$1.31B |
| Financing cash flow | -$91.40M | $7.90M | $374.70M | $4.70M | $278.60M |
| Depreciation & amortization | $3.00M | $4.60M | $4.80M | $6.30M | $4.80M |
| Stock-based compensation | $44.00M | $88.20M | $71.60M | $75.50M | $57.10M |
| Share buybacks | $91.90M | $0 | $0 | — | — |
Free plan shows the latest 5 periods; Pro shows all 9 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.